skimming under "Stanton", don't see anything conceptually (global) new here......
United States Patent Application 20020081620
Kind Code A1
Stanton, Vincent P. JR. June 27, 2002
--------------------------------------------------------------------------------
Probes for variance detection
Abstract
Disclosed are methods and reagents for detecting nucleotide mismatches (for example, due to sequence variances) in a nucleic acid sample involving the use of a nucleic acid probe derived from a hemizygous cell. Methods for determining the haplotype of a nucleic acid sample are also disclosed. Also disclosed are methods for producing the probe and kits containing the probe.
appft.uspto.gov:8080/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=2&f=G&l=50&co1=AND&d=PG01&s1=Stanton.IN.&OS=IN/Stanton&RS=IN/Stanton
United States Patent Application 20020012921
Kind Code A1
Stanton, Vincent P. JR. January 31, 2002
--------------------------------------------------------------------------------
Identification of genetic components of drug response
Abstract
The present invention is concerned generally with the field of identifying an appropriate treatment regimen for a disease based upon genotype in mammals, particularly in humans. It is further concerned with the genetic basis of inter-patient variation in response to therapy, including drug therapy. Specifically, this invention describes the identification of gene sequence variances useful in the field of therapeutics for optimizing efficacy and safety of drug therapy. These variances may be useful during the drug development process and in guiding the optimal use of already approved compounds. DNA sequence variances in candidate genes (i.e., genes that may plausibly affect the action of a drug) are tested in clinical trials, leading to the establishment of diagnostic tests useful for improving the development of new pharmaceutical products and/or the more effective use of existing pharmaceutical products. Methods for identifying genetic variances and determining their utility in the selection of optimal therapy for specific patients are also described. In general, the invention relates to methods for identifying patient population subsets that respond to drug therapy with either therapeutic benefit or side effects (i.e., symptomatology prompting concern about safety or other unwanted signs or symptoms).
appft.uspto.gov:8080/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=10&f=G&l=50&co1=AND&d=PG01&s1=Stanton.IN.&OS=IN/Stanton&RS=IN/Stanton
United States Patent Application 20020039990
Kind Code A1
Stanton, Vincent P. JR. April 4, 2002
--------------------------------------------------------------------------------
Gene sequence variances in genes related to folate metabolism having utility in determining the treatment of disease
Abstract
The present disclosure describes the use of genetic variance information for folate transport or metabolism genes or pyrimidine transport or metabolism genes in the selection of effective methods of treatment of a disease or condition. The variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.
appft.uspto.gov:8080/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=9&f=G&l=50&co1=AND&d=PG01&s1=Stanton.IN.&OS=IN/Stanton&RS=IN/Stanton |
